DIR Fee Clawbacks Grew 107,400% in a Decade, Bankrupting Small Pharmacies

Direct and Indirect Remuneration (DIR) fees are retroactive charges that PBMs impose on pharmacies, often six months or more after a Medicare Part D prescription has been filled. Between 2010 and 2020, the total amount of DIR fees collected from pharmacies grew by 107,400% according to the Centers for Medicare and Medicaid Services. These fees function as clawbacks: a pharmacy fills a prescription, receives a reimbursement at the point of sale, and then months later the PBM takes back a portion of that reimbursement based on opaque performance metrics that the pharmacy had no ability to predict at the time of dispensing. This creates an accounting nightmare that makes it impossible for independent pharmacies to know whether they are profitable on any given prescription until months after the fact. A pharmacy may fill a prescription believing it will break even, only to discover six months later that a DIR fee has turned that transaction into a net loss. Multiply this uncertainty across thousands of prescriptions per month and the result is a business that cannot reliably forecast its own cash flow. For small independent pharmacies operating on margins of 1-2%, a single large DIR fee clawback can wipe out an entire quarter's profit. CMS attempted to reform DIR fees effective January 1, 2024, requiring that all DIR fees be applied at the point of sale rather than retroactively. But the reform had unintended consequences: while retroactive clawbacks were eliminated, the point-of-sale adjustments often resulted in even lower upfront reimbursements, and PBMs introduced new fee categories -- Generic Effective Rate (GER) and Brand Effective Rate (BER) recoupments -- that function similarly to the old DIR fees under different names. This problem persists because the regulatory framework gives PBMs broad discretion to define performance metrics and fee structures. The pharmacy has no meaningful ability to negotiate these terms -- it either accepts the PBM's contract or loses access to that PBM's patient network. The power asymmetry is total: three PBMs control 80% of the market, and a pharmacy that refuses one PBM's terms loses roughly a quarter of its potential customers.